Intranasal cocaine use does not appear to be an independent risk factor for HCV infection

Addiction

Volumn 99, Issue 8, 2004, Pages 973-977

  Galperim, Bruno ^a,e   Cheinquer, Hugo ^b   Stein, Airton ^c   Fonseca, André ^d   Lunge, Vagner ^d   Ikuta, Nilo ^d  

^a HOSPITAL MÃE DE DEUS   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^d UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^e NONE   (Brazil)

Author keywords

Hepatitis C; Intranasal cocaine use; Intravenous drug use

Indexed keywords

AMINOTRANSFERASE; COCAINE; HEPATITIS C ANTIBODY; VIRUS RNA;

ADOLESCENT; ADULT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG USE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; QUESTIONNAIRE; REVIEW; RISK FACTOR; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; COCAINE DEPENDENCE; CROSS-SECTIONAL STUDY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; SUBSTANCE ABUSE;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; COCAINE; COCAINE-RELATED DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 7444267824     PISSN: 09652140     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2004.00761.x     Document Type: Review

References (21)

1. Almeida, P. R. L., Alves de Mattos, A., Ulbrich-Kutczynski, J., Czerski, C. T. & Geyer, G. (1998) Prevalência e impacto histopatológico da infecçāo pelo vírus C em doadores de sangue. [Prevalence and histopathologic impact of hepatitis C virus in blood donors]. Gastrenterologia Endoscopia Digestiva, 17, 121-128.
2. Alter, M. J. (1997) Epidemiology of hepatitis C. Hepatology, 26, 625-655.
3. Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A. & Margolis, H. S. (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New England Journal of Medicine, 341, 556-562.
4. Altman, D. G. (1991) Practical Statistics for Medical Research. London: Chapman & Hall.
5. Baozhang, T., Kaining, Z., Jinxing, K., Ruchang, X., Ming, L., Caixia, Z. & Li, T. (1997) Infection with human immunodeficiency virus and hepatitis viruses in Chinese drug addicts. Epidemiology Infection, 119, 333-347.
6. Centres for Disease Control (CDC) (1998) Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic liver diseases. Mortality and Morbidity Weekly Report, 47, 1-39.
7. Conry-Cantilena, C., Vanraden, M., Gibble, J., Melpolder, J., Shakil, A. O., Viladomiu, L., Cheung, L., DiBisceglie, A., Hoofnagle, J., Shih, J. W., Kaslow, R., Ness, P. & Alter, H. J. (1996) Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. New England Journal of Medicine, 334, 1691-1696.
8. Fingerhood, M. I., Jasinski, D. R. & Sullivan, J. T. (1993) Prevalence of hepatitis C in a chemically dependent population. Archives of International Medicine, 153, 2025-2030.
9. Fletcher, R. H., Fletcher, S. W. & Wagner, E. H. (1996) Epidemiologia clinica: elementos essenciais [Clinical Epidemiology: Essential Elements], 3rd edn. Porto Alegre: Artes Médicas.
10. Krug, L. P., Lunge, V. R., Ikuta, N., Fonseca, A. S., Cheinquer, H., Ozaki, L. S. & Barros, S. G. (1996) Hepatitis C virus genotypes in Southern Brazil. Brazilian Journal of Medical Biological Research, 29, 1629-1632.
11. Maayan, S., Shufman, E. N., Engelhard, D. & Shouval, D. (1994) Exposure to hepatitis B and C and to HTLV-1 and 2 among Israeli drug abusers in Jerusalem. Addiction, 89, 869-874.
12. Murphy, E. L., Bryzman, S. M., Glynn, A. S., Ameti, D. I., Thomson, R. A., Williams, A. E., Nass, C. C., . Ownby, H. E., Schreiber, G. B., Kong, F., Neal, K. R. & Nemo, G. J. (2000) Risk factors for hepatitis C virus infection in United States blood donors. Hepatology, 31, 756-762.
13. Murphy, E. L., Bryzman, S. & Williams, A. E. (1999) Prevalence of hepatitis C virus infection in the United States. New England Journal of Medicine, 341, 2093-2095.
14. Simmonds, P., McOmish, F., Yap, P. L., Chan, S. W., Lin, C. K., Dusheiko, G., Saeed, A. A. & Holmes, E. C. (1993) Sequence variability in the 5′ non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. Journal of General Virology. 74, 661-668.
15. Sookoian, S., Castaño, G., Castiglioni, T., Filar, S., Viudez, P., Gonzalez, J. & Frieder, B. (1997) Problematica de la infeccion por el virus de la hepatitis C en douantes de sangre. Evaluacion clinico-epidemiologica, virologica e histologica [Problems in hepatitis C infection in blood donors. Clinical epidemiology, virology and histology evaluation]. Medicina (Buenos Aires), 57, 699-707.
16. Thomas, D. L. (2000) Hepatitis C epidemiology: injecting new tools in the field. Hepatology, 31, 790-791.
17. Van den Hoek, J. A. R., Van Haastrecht, H. J. A., Goudsmit, J., de Wolf, F. & Coutinho, R. A. (1990) Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. Journal of Infectious Diseases, 162, 823-826.
18. Woodfield, G. D., Harness, M. & Rix-Trott, K. (1993) Hepatitis C virus infections in oral and injectable drug users. New Zealand Medical Journal, 106, 332-334.
19. Woodfield, G. D., Harness, M., Rix-Trott, K., Tsuda, F., Okamoto, H. & Mayumi, M. (1994) Identification and genotyping of hepatitis C virus in injectable and oral drug users in New Zealand. Australian and New Zealand Journal of Medicine, 24, 47-50.
20. World Health Organization (WHO) (1992) The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnosis Guidelines. Geneva: WHO.
21. World Health Organization (WHO) (1997) Weekly Epidemiological Record, 72, 65-72.